Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy.

IF 1.4 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Damla Raimoglou, Cemil İzgi, Rasim Enar, M Hakan Karpuz, Bilgehan Karadağ, Barış İktimur, Utku Raimoğlu, Ali Uğur Soysal, Osman Aykan Kargın, Mehmet Güven, Namina Malikova, Elif Çıtak, Ece Yurtseven, Eser Durmaz
{"title":"Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy.","authors":"Damla Raimoglou, Cemil İzgi, Rasim Enar, M Hakan Karpuz, Bilgehan Karadağ, Barış İktimur, Utku Raimoğlu, Ali Uğur Soysal, Osman Aykan Kargın, Mehmet Güven, Namina Malikova, Elif Çıtak, Ece Yurtseven, Eser Durmaz","doi":"10.14744/AnatolJCardiol.2023.3898","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertrophic cardiomyopathy (HCM) is a genetically inherited cardiac disorder with diverse clinical presentations. Adrenergic activity, primarily mediated through beta-adrenoceptors, plays a central role in the clinical course of HCM. Adrenergic stimulation increases cardiac contractility and heart rate through beta-1 adrenoceptor activation. Beta-blocker drugs are recommended as the primary treatment for symptomatic HCM patients to mitigate these effects.</p><p><strong>Methods: </strong>This prospective study aimed to investigate the impact of common ADRB-1 gene polymorphisms, specifically serine-glycine at position 49 and arginine-glycine at position 389, on the clinical and structural aspects of HCM. Additionally, the study explored the association between these genetic variations and the response to beta-blocker therapy in HCM patients.</p><p><strong>Results: </strong>A cohort of 147 HCM patients was enrolled, and comprehensive assessments were performed. The findings revealed that the Ser49Gly polymorphism significantly influenced ventricular ectopic beats, with beta-blocker therapy effectively reducing them in Ser49 homozygous patients. Moreover, natriuretic peptide levels decreased, particularly in Ser49 homozygotes, indicating improved cardiac function. Left ventricular outflow obstruction, a hallmark of HCM, was also reduced following beta-blocker treatment in all patient groups. In contrast, the Arg389Gly polymorphism did not significantly impact baseline parameters or beta-blocker response.</p><p><strong>Conclusion: </strong>These results emphasize the role of the Ser49Gly polymorphism in the ADRB-1 gene in shaping the clinical course and response to beta-blocker therapy in HCM patients. This insight may enable a more personalized approach to managing HCM by considering genetic factors in treatment decisions. Further research with larger populations and longer follow-up periods is needed to confirm and expand upon these findings.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918278/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anatolian Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14744/AnatolJCardiol.2023.3898","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is a genetically inherited cardiac disorder with diverse clinical presentations. Adrenergic activity, primarily mediated through beta-adrenoceptors, plays a central role in the clinical course of HCM. Adrenergic stimulation increases cardiac contractility and heart rate through beta-1 adrenoceptor activation. Beta-blocker drugs are recommended as the primary treatment for symptomatic HCM patients to mitigate these effects.

Methods: This prospective study aimed to investigate the impact of common ADRB-1 gene polymorphisms, specifically serine-glycine at position 49 and arginine-glycine at position 389, on the clinical and structural aspects of HCM. Additionally, the study explored the association between these genetic variations and the response to beta-blocker therapy in HCM patients.

Results: A cohort of 147 HCM patients was enrolled, and comprehensive assessments were performed. The findings revealed that the Ser49Gly polymorphism significantly influenced ventricular ectopic beats, with beta-blocker therapy effectively reducing them in Ser49 homozygous patients. Moreover, natriuretic peptide levels decreased, particularly in Ser49 homozygotes, indicating improved cardiac function. Left ventricular outflow obstruction, a hallmark of HCM, was also reduced following beta-blocker treatment in all patient groups. In contrast, the Arg389Gly polymorphism did not significantly impact baseline parameters or beta-blocker response.

Conclusion: These results emphasize the role of the Ser49Gly polymorphism in the ADRB-1 gene in shaping the clinical course and response to beta-blocker therapy in HCM patients. This insight may enable a more personalized approach to managing HCM by considering genetic factors in treatment decisions. Further research with larger populations and longer follow-up periods is needed to confirm and expand upon these findings.

肾上腺素受体β-1基因多态性对肥厚型心肌病患者的结构和功能影响以及对β-受体阻滞剂治疗的反应
背景:肥厚型心肌病(HCM)是一种遗传性心脏疾病,临床表现多种多样。肾上腺素能活动主要通过β-肾上腺素受体介导,在 HCM 的临床过程中起着核心作用。肾上腺素能刺激可通过激活 beta-1 肾上腺素受体增加心脏收缩力和心率。建议将β-受体阻滞剂作为无症状 HCM 患者的主要治疗药物,以减轻这些影响:这项前瞻性研究旨在调查常见的 ADRB-1 基因多态性(特别是第 49 位的丝氨酸-甘氨酸和第 389 位的精氨酸-甘氨酸)对 HCM 临床和结构方面的影响。此外,该研究还探讨了这些基因变异与 HCM 患者对β-受体阻滞剂治疗的反应之间的关联:结果:研究人员招募了 147 名 HCM 患者,并对他们进行了全面评估。研究结果显示,Ser49Gly 多态性对心室异位搏动有显著影响,β-受体阻滞剂治疗可有效减少 Ser49 基因同型患者的心室异位搏动。此外,钠尿肽水平也有所下降,尤其是在 Ser49 基因同型患者中,这表明心脏功能有所改善。左心室流出道梗阻是 HCM 的特征之一,所有患者组在接受β-受体阻滞剂治疗后,左心室流出道梗阻也有所减轻。相比之下,Arg389Gly 多态性对基线参数或β-受体阻滞剂反应没有显著影响:这些结果强调了 ADRB-1 基因中的 Ser49Gly 多态性在影响 HCM 患者的临床过程和对β-受体阻滞剂治疗的反应中的作用。这种认识有助于在做出治疗决定时考虑遗传因素,从而采用更加个性化的方法来治疗 HCM。还需要对更大的人群和更长的随访期进行进一步研究,以证实和扩展这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anatolian Journal of Cardiology
Anatolian Journal of Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.30
自引率
7.70%
发文量
270
审稿时长
12 weeks
期刊介绍: The Anatolian Journal of Cardiology is an international monthly periodical on cardiology published on independent, unbiased, double-blinded and peer-review principles. The journal’s publication language is English. The Anatolian Journal of Cardiology aims to publish qualified and original clinical, experimental and basic research on cardiology at the international level. The journal’s scope also covers editorial comments, reviews of innovations in medical education and practice, case reports, original images, scientific letters, educational articles, letters to the editor, articles on publication ethics, diagnostic puzzles, and issues in social cardiology. The target readership includes academic members, specialists, residents, and general practitioners working in the fields of adult cardiology, pediatric cardiology, cardiovascular surgery and internal medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信